For example, administration of IL-2 in patients with systemic lupus erythematosus (SLE) ameliorated disease via the expansion of Tregs without an increased risk of infection, and low dose IL-2 therapy is being investigated in T1D (22–25). Here, IL2 is linked to type 1 diabetes mellitus.